In a study recently presented at the European Academy of Dermatology and Venerology (EADV) Congress 2024, it was revealed that semaglutide has the potential to treat hidradenitis suppurative (HS) in patients with obesity.
Hidradenitis suppurativa, a common chronic skin condition affecting approximately 1 in 100 people, is characterized by painful abscesses and scarring. Beyond the physical pain and discomfort, HS can significantly impact an individual’s quality of life, making everyday activities and social interactions challenging.
With obesity being a significant risk factor for the development of HS, this research is considered groundbreaking as it explores the potential of semaglutide as a treatment option for the condition.
The study evaluated data from June 2020 to March 2023, looking at health outcomes for a total of 30 patients with obesity with varying stages of HS. Patients were given semaglutide, a glucagon-like peptide-1 receptor agonist, once a week with a mean dose of 0.8mg. This was done for an average of 8.2 months.
The research aimed to evaluate the efficacy of semaglutide in reducing HS flare-ups, improving the patient’s quality of life, and promoting weight loss.
Results showed that patients experienced fewer flare-ups of HS, and the frequency of these episodes reduced from an average of once every 8.5 weeks to once every 12 weeks. Patient quality of life also showed significant improvement. This was measured as a reduction of the Dermatology Life Quality Index (DQLI) score from an average of 13/30 to 9/30.
Furthermore, results demonstrated a decrease in the average BMI of patients, from 43.1 to 41.5. Their mean weight also showed a significant decrease, from 117.7kg to 111.6kg. It is noted that one-third of patients in the study lost 10kg or more during the treatment period.
It was further reported that patients in the study showed a decrease in HbA1c levels from 39.3 to 36.6, which indicated better glycaemic control. In addition, the average CRP levels fell from 7.8 to 6.9, demonstrating a reduction in inflammation.
According to lead researcher, Daniel Lyons, MD,”Our findings suggest that semaglutide, even at modest doses, can offer substantial benefits in managing HS. While the drug’s role in promoting weight loss is well-established, what’s particularly exciting is its potential to also reduce the frequency of HS flare-ups, contributing to the notable improvements observed in patients’ quality of life.”
